<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Eur J Clin Invest</journal-id><journal-id journal-id-type="iso-abbrev">Eur. J. Clin. Invest</journal-id><journal-id journal-id-type="doi">10.1111/(ISSN)1365-2362</journal-id><journal-id journal-id-type="publisher-id">ECI</journal-id><journal-title-group><journal-title>European Journal of Clinical Investigation</journal-title></journal-title-group><issn pub-type="ppub">0014-2972</issn><issn pub-type="epub">1365-2362</issn><publisher><publisher-name>John Wiley and Sons Inc.</publisher-name><publisher-loc>Hoboken</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">28556061</article-id><article-id pub-id-type="pmc">5519937</article-id><article-id pub-id-type="doi">10.1111/eci.12771</article-id><article-id pub-id-type="publisher-id">ECI12771</article-id><article-categories><subj-group subj-group-type="overline"><subject>Original Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Original Articles</subject></subj-group></article-categories><title-group><article-title>Acetylsalicylic acid in critically ill patients: a cross&#x02010;sectional and a randomized trial</article-title><alt-title alt-title-type="left-running-head">C. Schoergenhofer <italic>et al</italic>.</alt-title></title-group><contrib-group><contrib id="eci12771-cr-0001" contrib-type="author"><name><surname>Schoergenhofer</surname><given-names>Christian</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-2286-1077</contrib-id><xref ref-type="aff" rid="eci12771-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="eci12771-cr-0002" contrib-type="author"><name><surname>Hobl</surname><given-names>Eva&#x02010;Luise</given-names></name><xref ref-type="aff" rid="eci12771-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="eci12771-cr-0003" contrib-type="author"><name><surname>Schwameis</surname><given-names>Michael</given-names></name><xref ref-type="aff" rid="eci12771-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="eci12771-cr-0004" contrib-type="author"><name><surname>Gelbenegger</surname><given-names>Georg</given-names></name><xref ref-type="aff" rid="eci12771-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="eci12771-cr-0005" contrib-type="author"><name><surname>Staudinger</surname><given-names>Thomas</given-names></name><xref ref-type="aff" rid="eci12771-aff-0002">
<sup>2</sup>
</xref></contrib><contrib id="eci12771-cr-0006" contrib-type="author"><name><surname>Heinz</surname><given-names>Gottfried</given-names></name><xref ref-type="aff" rid="eci12771-aff-0003">
<sup>3</sup>
</xref></contrib><contrib id="eci12771-cr-0007" contrib-type="author"><name><surname>Speidl</surname><given-names>Walter S.</given-names></name><xref ref-type="aff" rid="eci12771-aff-0003">
<sup>3</sup>
</xref></contrib><contrib id="eci12771-cr-0008" contrib-type="author"><name><surname>Zauner</surname><given-names>Christian</given-names></name><xref ref-type="aff" rid="eci12771-aff-0004">
<sup>4</sup>
</xref></contrib><contrib id="eci12771-cr-0009" contrib-type="author"><name><surname>Reiter</surname><given-names>Birgit</given-names></name><xref ref-type="aff" rid="eci12771-aff-0005">
<sup>5</sup>
</xref></contrib><contrib id="eci12771-cr-0010" contrib-type="author"><name><surname>Lang</surname><given-names>Irene</given-names></name><xref ref-type="aff" rid="eci12771-aff-0003">
<sup>3</sup>
</xref></contrib><contrib id="eci12771-cr-0011" contrib-type="author" corresp="yes"><name><surname>Jilma</surname><given-names>Bernd</given-names></name><address><email>bernd.jilma@meduniwien.ac.at</email></address><xref ref-type="aff" rid="eci12771-aff-0001">
<sup>1</sup>
</xref></contrib></contrib-group><aff id="eci12771-aff-0001">
<label><sup>1</sup></label>
<named-content content-type="organisation-division">Department of Clinical Pharmacology</named-content>
<institution>Medical University of Vienna</institution>
<named-content content-type="city">Vienna</named-content>
<country>Austria</country>
</aff><aff id="eci12771-aff-0002">
<label><sup>2</sup></label>
<named-content content-type="organisation-division">Department of Internal Medicine I Oncology &#x00026; Hematology</named-content>
<institution>Medical University of Vienna</institution>
<named-content content-type="city">Vienna</named-content>
<country country="AT">Austria</country>
</aff><aff id="eci12771-aff-0003">
<label><sup>3</sup></label>
<named-content content-type="organisation-division">Department of Internal Medicine II Cardiology</named-content>
<institution>Medical University of Vienna</institution>
<named-content content-type="city">Vienna</named-content>
<country country="AT">Austria</country>
</aff><aff id="eci12771-aff-0004">
<label><sup>4</sup></label>
<named-content content-type="organisation-division">Department of Internal Medicine III Gastroenterology &#x00026; Hepatology</named-content>
<institution>Medical University of Vienna</institution>
<named-content content-type="city">Vienna</named-content>
<country country="AT">Austria</country>
</aff><aff id="eci12771-aff-0005">
<label><sup>5</sup></label>
<named-content content-type="organisation-division">Clinical Institute of Laboratory Medicine</named-content>
<named-content content-type="organisation-division">Forensic Toxicology Unit</named-content>
<institution>Medical University of Vienna</institution>
<named-content content-type="city">Vienna</named-content>
<country country="AT">Austria</country>
</aff><author-notes><corresp id="correspondenceTo"><label>*</label><bold>Correspondence to:</bold> Bernd Jilma, Department of Clinical Pharmacology, Medical University of Vienna, W&#x000e4;hringer G&#x000fc;rtel 18&#x02010;20, 1090 Vienna, Austria. Tel.: +43 1 40400 29810; fax: +43 1 40400 29980; e&#x02010;mail: <email>bernd.jilma@meduniwien.ac.at</email></corresp></author-notes><pub-date pub-type="epub"><day>20</day><month>6</month><year>2017</year></pub-date><pub-date pub-type="ppub"><month>7</month><year>2017</year></pub-date><volume>47</volume><issue>7</issue><issue-id pub-id-type="doi">10.1111/eci.2017.47.issue-7</issue-id><fpage>504</fpage><lpage>512</lpage><history><date date-type="received"><day>24</day><month>3</month><year>2017</year></date><date date-type="accepted"><day>23</day><month>5</month><year>2017</year></date></history><permissions><!--<copyright-statement content-type="issue-copyright"> Copyright &#x000a9; 2017 Stichting European Society for Clinical Investigation Journal Foundation. Published by John Wiley & Sons Ltd <copyright-statement>--><copyright-statement content-type="article-copyright">&#x000a9; 2017 The Authors. <italic>European Journal of Clinical Investigation</italic> published by John Wiley &#x00026; Sons Ltd on behalf of Stichting European Society for Clinical Investigation Journal Foundation</copyright-statement><license license-type="creativeCommonsBy"><license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri content-type="pdf" xlink:type="simple" xlink:href="file:ECI-47-504.pdf"/><abstract id="eci12771-abs-0001"><title>Abstract</title><sec id="eci12771-sec-0001"><title>Background</title><p>Despite decades of clinical use, the pharmacokinetics and the effects of acetylsalicylic acid (<styled-content style="fixed-case">ASA</styled-content>) in critically ill patients remain ill&#x02010;defined. We aimed to investigate the pharmacokinetics and the effects of different <styled-content style="fixed-case">ASA</styled-content> formulations during critical illness.</p></sec><sec id="eci12771-sec-0002"><title>Design</title><p>A cross&#x02010;sectional study and a randomized, parallel&#x02010;group trial were performed. Critically ill patients under chronic oral <styled-content style="fixed-case">ASA</styled-content> treatment (100 mg enteric&#x02010;coated) were screened for high &#x02018;on&#x02010;treatment&#x02019; platelet reactivity (<styled-content style="fixed-case">HTPR</styled-content>) according to arachidonic acid&#x02010;induced whole&#x02010;blood aggregometry. Thirty patients with <styled-content style="fixed-case">HTPR</styled-content> were randomized to receive 100 mg <styled-content style="fixed-case">ASA</styled-content> intravenously, 100 mg enteric&#x02010;coated <styled-content style="fixed-case">ASA</styled-content> bid (bis in die) or 81 mg chewable <styled-content style="fixed-case">ASA</styled-content> (<italic>n</italic> = 10 per group). Serum thromboxane B2 (<styled-content style="fixed-case">TXB</styled-content>2) levels, <styled-content style="fixed-case">ASA</styled-content> and salicylic acid levels were quantified.</p></sec><sec id="eci12771-sec-0003"><title>Results</title><p>Of 66 patients, 85% (95% confidence intervals 74&#x02013;93%) had <styled-content style="fixed-case">HTPR</styled-content>. Compared to baseline infusion of 100 mg, <styled-content style="fixed-case">ASA</styled-content> significantly reduced platelet aggregation after 24 h to median 80% (Quartiles: 66&#x02013;84%). Intake of 81 mg chewable <styled-content style="fixed-case">ASA</styled-content> significantly reduced platelet aggregation to 75% (54&#x02013;86%) after four hours, but increased it to 117% after 24 h (81&#x02013;163%). Treatment with 100 mg enteric&#x02010;coated <styled-content style="fixed-case">ASA</styled-content> bid decreased platelet aggregation after 24 h to median 56% (52&#x02013;113%). Baseline <styled-content style="fixed-case">TXB</styled-content>2 levels were median 0&#x000b7;35 ng/mL (0&#x000b7;07&#x02013;0&#x000b7;94). Infusion of <styled-content style="fixed-case">ASA</styled-content> or intake of 100 mg <styled-content style="fixed-case">ASA</styled-content> bid reduced <styled-content style="fixed-case">TXB</styled-content>2 levels to 0&#x000b7;07&#x02013;0&#x000b7;18 ng/mL after 24 h, respectively. Chewable <styled-content style="fixed-case">ASA</styled-content> reduced <styled-content style="fixed-case">TXB</styled-content>2 levels only transiently. Pharmacokinetic analysis revealed highly variable absorption patterns of oral <styled-content style="fixed-case">ASA</styled-content> formulations.</p></sec><sec id="eci12771-sec-0004"><title>Conclusion</title><p>There is a very high prevalence of <styled-content style="fixed-case">HTPR</styled-content> in critically ill patients on peroral <styled-content style="fixed-case">ASA</styled-content> therapy, caused by an incomplete suppression of <styled-content style="fixed-case">TXB</styled-content>2 and/or by impaired absorption of <styled-content style="fixed-case">ASA</styled-content>.</p></sec></abstract><kwd-group kwd-group-type="author-generated"><kwd id="eci12771-kwd-0001">Acetylsalicylic acid</kwd><kwd id="eci12771-kwd-0002">critically ill</kwd><kwd id="eci12771-kwd-0003">pharmacokinetics</kwd><kwd id="eci12771-kwd-0004">platelet aggregation</kwd><kwd id="eci12771-kwd-0005">thromboxane</kwd></kwd-group><funding-group><award-group><funding-source>Austrian Science Funds</funding-source><award-id>SFB54P04</award-id></award-group></funding-group><counts><fig-count count="4"/><table-count count="1"/><page-count count="9"/><word-count count="5525"/></counts><custom-meta-group><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>component-id</meta-name><meta-value>eci12771</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>July 2017</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_NLMPMC version:5.1.4 mode:remove_FC converted:21.07.2017</meta-value></custom-meta></custom-meta-group></article-meta><notes><p content-type="self-citation">
<mixed-citation publication-type="journal" id="eci12767-cit-1001">
<source>Eur J Clin Invest</source>
<year>2017</year>; <volume>47</volume> (<issue>7</issue>): <fpage>504</fpage>&#x02013;<lpage>512</lpage>
<pub-id pub-id-type="pmid">28556061</pub-id></mixed-citation>
</p></notes></front><body><sec id="eci12771-sec-0005"><title>Introduction</title><p>For decades, acetylsalicylic acid (ASA) has been a mainstay in the secondary prophylaxis of cardiovascular diseases <xref rid="eci12771-bib-0001" ref-type="ref">1</xref>, whereas its role in primary prevention remains debatable <xref rid="eci12771-bib-0002" ref-type="ref">2</xref>. Intake of low&#x02010;dose ASA was associated with improved outcome in critically ill patients <xref rid="eci12771-bib-0003" ref-type="ref">3</xref>, in patients with <italic>Staphylococcus aureus</italic> bloodstream infections <xref rid="eci12771-bib-0004" ref-type="ref">4</xref> or in patients with septic shock from community&#x02010;acquired pneumonia <xref rid="eci12771-bib-0005" ref-type="ref">5</xref>.</p><p>High on&#x02010;treatment platelet reactivity (HTPR) is defined as an insufficient inhibition of platelets despite antiplatelet therapy that may be associated with an increased risk of experiencing cardiovascular events <xref rid="eci12771-bib-0006" ref-type="ref">6</xref>. In contrast to P2Y12 inhibitors, no well&#x02010;defined thresholds exist for treatment with ASA <xref rid="eci12771-bib-0006" ref-type="ref">6</xref>. Depending on cut&#x02010;offs and platelet function tests, the prevalence of HTPR ranges between ~20% and 30% <xref rid="eci12771-bib-0007" ref-type="ref">7</xref>, <xref rid="eci12771-bib-0008" ref-type="ref">8</xref>.</p><p>Surprisingly, no data are available on the prevalence of HTPR or on the pharmacokinetics of ASA in critically ill patients. However, the pharmacological properties of drugs during critical illness may be significantly altered, that is due to impaired gastric motility, altered bioavailability after enteral administration, altered drug distribution, organ dysfunction or altered enzyme activity <xref rid="eci12771-bib-0009" ref-type="ref">9</xref>, <xref rid="eci12771-bib-0010" ref-type="ref">10</xref>, <xref rid="eci12771-bib-0011" ref-type="ref">11</xref>. Furthermore, critically ill patients may have an increased platelet turnover with increased risk of HTPR <xref rid="eci12771-bib-0012" ref-type="ref">12</xref>.</p><p>We hypothesized that HTPR is frequent in critically ill patients because of altered pharmacokinetics and systemic inflammation. The aim of this trial was to investigate the drug concentrations and the antiplatelet effects of low&#x02010;dose ASA in critically ill patients. Furthermore, we investigated whether a second dose, an intravenous infusion or an alternative formulation of ASA, improves the response to ASA in poor responders to standard ASA treatment.</p></sec><sec id="eci12771-sec-0006"><title>Materials and methods</title><p>The Department of Clinical Pharmacology of the Medical University of Vienna coordinated the trial and included patients admitted to medical ICUs of the General Hospital of Vienna. The independent Ethics Committee of the Medical University of Vienna and the competent authorities approved the trial, which was conducted in full commitment with the Declaration of Helsinki and the Good Clinical Practice guideline. The project was registered at clinicaltrials.gov and at EudraCT with the identifiers NCT02285751 and 2012&#x02010;002226&#x02010;76, respectively. Informed consent was sought from all patients before inclusion. However, in patients unable to give informed consent at the time of inclusion, the ethics committee waived consent. The protocol was uploaded as a supplement. Reporting of the study conforms to CONSORT&#x02010;revised along with references to CONSORT&#x02010;revised and the broader EQUATOR guidelines <xref rid="eci12771-bib-0013" ref-type="ref">13</xref>.</p><sec id="eci12771-sec-0007"><title>Patients</title><p>Inclusion criteria requested patients &#x0003e; 18 years of age, admitted to a medical ICU with pre&#x02010;existent low&#x02010;dose ASA treatment [oral 100 mg/day enteric&#x02010;coated ASA (Thrombo&#x02010;ASS, Gerot Lannach Pharma, Lannach, Austria)]. Exclusion criteria included allergies or hypersensitivities to the trial drugs, active bleeding, known coagulation disorders or intake of other antiplatelet drugs.</p></sec><sec id="eci12771-sec-0008"><title>Noninterventional trial</title><p>Blood samples were drawn before the daily dose of ASA was administered, orally or via a nasogastric tube, 2 and 24 h thereafter. ASA tablets had to be crushed and/or dissolved in 0&#x000b7;9% sodium chloride solution, if they were administered via a nasogastric tube.</p></sec><sec id="eci12771-sec-0009"><title>Interventional trial</title><p>In this open&#x02010;label trial, thirty patients diagnosed with HTPR were randomized to receive 81 mg chewable ASA (Bayer chewable aspirin, Morristown, NJ, USA, <italic>n</italic> = 10), 100 mg intravenous ASA (Aspisol, Bayer Schering Pharma, Berlin, Germany, <italic>n</italic> = 10) or 100 mg enteric&#x02010;coated ASA bis in die (bid, twice daily) at 8:00 a.m. and 8:00 p.m. (<italic>n</italic> = 10) for 1 day. Blood sampling was performed 1, 2, 4 and 24 h after the respective treatment was administered.</p></sec><sec id="eci12771-sec-0010"><title>Platelet function assays</title><p>To assess platelet function, we performed arachidonic acid (AA)&#x02010;induced whole&#x02010;blood aggregometry and measured platelet function under high shear rates, both standard methods to assess responsiveness to ASA treatment <xref rid="eci12771-bib-0014" ref-type="ref">14</xref>.</p><p>Whole&#x02010;blood aggregation was determined using the multiple electrode aggregometry (MEA) on the Multiplate Analyzer (Dynabyte Medical, Munich, Germany). AA&#x02010; and ADP&#x02010;induced platelet aggregation were performed as explained previously <xref rid="eci12771-bib-0015" ref-type="ref">15</xref> (Appendix <xref rid="eci12771-sup-0001" ref-type="supplementary-material">S1</xref>). Based on other trials, we chose a cut&#x02010;off of &#x0003e; 30 U (arbitrary units) <xref rid="eci12771-bib-0016" ref-type="ref">16</xref>, <xref rid="eci12771-bib-0017" ref-type="ref">17</xref>, <xref rid="eci12771-bib-0018" ref-type="ref">18</xref>.</p><p>The platelet function analyzer&#x02010;100 (PFA&#x02010;100; Dade Behring, Marburg, Germany) was used for measuring platelet function under high shear rates (5000&#x02013;6000 s<sup>&#x02212;1</sup>) as described previously <xref rid="eci12771-bib-0019" ref-type="ref">19</xref> (Appendix <xref rid="eci12771-sup-0001" ref-type="supplementary-material">S1</xref>). Collagen/epinephrine (PFA&#x02010;EPI) and collagen/ADP (PFA&#x02010;ADP) coated cartridges were used. As a cut&#x02010;off value for HTPR, a closure time &#x0003c; 193 s for PFA&#x02010;EPI was recommended <xref rid="eci12771-bib-0020" ref-type="ref">20</xref>.</p><p>Thromboxane B2 (TXB2) levels were measured by enzyme&#x02010;linked immunoassay (ELISA; Cayman Chemical, Ann Arbor, MI, USA) as previously reported <xref rid="eci12771-bib-0020" ref-type="ref">20</xref>.</p></sec><sec id="eci12771-sec-0011"><title>Pharmacokinetics</title><p>Plasma concentrations of ASA and salicylic acid were determined by liquid chromatography tandem mass spectrometry (LC&#x02010;MS/MS) based on a published procedure (Appendix <xref rid="eci12771-sup-0001" ref-type="supplementary-material">S1</xref>) <xref rid="eci12771-bib-0021" ref-type="ref">21</xref>.</p></sec><sec id="eci12771-sec-0012"><title>Disease scores</title><p>The Sequential Organ Failure Assessment (SOFA) score and the simplified acute physiology score (SAPS) III were calculated on trial day 1 <xref rid="eci12771-bib-0022" ref-type="ref">22</xref>, <xref rid="eci12771-bib-0023" ref-type="ref">23</xref>.</p></sec><sec id="eci12771-sec-0013"><title>Randomization</title><p>Physicians enrolled patients, who were assigned continuous identification numbers. Patients with HTPR on trial day 1 were available for randomization. Physicians or a trained study nurse randomized patients through an online randomization programme (<ext-link ext-link-type="uri" xlink:href="https://www.meduniwien.ac.at/randomizer/web/login.php">https://www.meduniwien.ac.at/randomizer/web/login.php</ext-link>) using permuted block randomization.</p></sec><sec id="eci12771-sec-0014"><title>Statistics</title><p>No data were available on the prevalence of HTPR in ICU patients. In stable patients, a HTPR rate of 20&#x02013;30% was reported <xref rid="eci12771-bib-0007" ref-type="ref">7</xref>, <xref rid="eci12771-bib-0008" ref-type="ref">8</xref>. To randomize 30 patients, we assumed that we need to screen a multiple of that and initially planned to include at least 100 patients. However, due to the high rate of HTPR in critically ill patients we finished the trial after inclusion of 66 patients.</p><p>We estimated a mean area under the curve (AUC) of 30 U in AA&#x02010;induced platelet aggregation in patients with HTPR <xref rid="eci12771-bib-0018" ref-type="ref">18</xref>. Thus, a sample of <italic>n</italic> = 10 per group allowed us to detect a significant reduction in platelet function from an AUC of 30 to 10 with a power of &#x0003e; 90% and a corrected alpha error of 1&#x000b7;6%. HTPR rates are presented as percentage &#x000b1; 95% confidence intervals (CI).</p><p>The primary endpoint was AA&#x02010;induced platelet aggregation. Secondary endpoints included drug concentrations, platelet function under high shear rates, TXB2 concentrations and correlations.</p><p>A repeated&#x02010;measures <sc>anova</sc> was performed to compare repeatedly measured parameters (in detail: Appendix <xref rid="eci12771-sup-0001" ref-type="supplementary-material">S1</xref>). To adjust for multiple comparisons, we performed the Bonferroni procedure.</p><p>For exploratory analysis, pairwise comparisons were performed by the Wilcoxon test, and unpaired comparisons with the Kruskal&#x02013;Wallis <sc>anova</sc> followed by a Mann&#x02013;Whitney <italic>U</italic>&#x02010;test. Due to the exploratory character of these analyses, no corrections for multiple testing were applied. Correlations were calculated using the nonparametric Spearman test.</p></sec></sec><sec id="eci12771-sec-0015"><title>Results</title><p>Sixty&#x02010;six critically ill patients were recruited and finished the trial between 13 November 2012 and 25 March 2016 (Fig. <xref rid="eci12771-fig-0001" ref-type="fig">1</xref>). The trial ended after the last visit of the last patient. Patient demographics and baseline data are presented in Table <xref rid="eci12771-tbl-0001" ref-type="table-wrap">1</xref>. The 28&#x02010;day mortality was 38%, which corresponded well with the predicted mortality from the simplified acute physiology score 3 <xref rid="eci12771-bib-0022" ref-type="ref">22</xref>. All randomized patients completed the trial per protocol, and data were available for all analyses, while in the observational part, 24&#x02010;h values of nine subjects were missing (Fig. <xref rid="eci12771-fig-0001" ref-type="fig">1</xref>).</p><fig fig-type="Figure" xml:lang="en" id="eci12771-fig-0001" orientation="portrait" position="float"><label>Figure 1</label><caption><p>Flow chart of the trial.</p></caption><graphic id="nlm-graphic-1" xlink:href="ECI-47-504-g001"/></fig><table-wrap id="eci12771-tbl-0001" xml:lang="en" orientation="portrait" position="float"><label>Table 1</label><caption><p>Demographics and baseline data</p></caption><table frame="hsides" rules="groups"><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><thead valign="top"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="top" rowspan="1" colspan="1">Parameter</th><th align="center" valign="top" rowspan="1" colspan="1">Mean &#x000b1; Standard deviation<xref ref-type="fn" rid="eci12771-note-0001">a</xref>
</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Gender m (f)</td><td align="char" char="(" rowspan="1" colspan="1">51 (15)</td></tr><tr><td align="left" rowspan="1" colspan="1">Age (years)</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">67 &#x000b1; 13</td></tr><tr><td align="left" rowspan="1" colspan="1">Height (cm)</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">174 &#x000b1; 8</td></tr><tr><td align="left" rowspan="1" colspan="1">Weight (kg)</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">85 &#x000b1; 20</td></tr><tr><td align="left" rowspan="1" colspan="1">Haemoglobin (g/dL)</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">9&#x000b7;8 &#x000b1; 1&#x000b7;4</td></tr><tr><td align="left" rowspan="1" colspan="1">Platelets (10<sup>9</sup>)</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">200 &#x000b1; 100</td></tr><tr><td align="left" rowspan="1" colspan="1">Leucocytes (10<sup>9</sup>)</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">11&#x000b7;1 &#x000b1; 4&#x000b7;3</td></tr><tr><td align="left" rowspan="1" colspan="1">C&#x02010;reactive protein (mg/dL)</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">12&#x000b7;0 &#x000b1; 9&#x000b7;1</td></tr><tr><td align="left" rowspan="1" colspan="1">SAPS 3 score trial day (points)</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">61 &#x000b1; 14</td></tr><tr><td align="left" rowspan="1" colspan="1">SOFA score (points)</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">7 &#x000b1; 4</td></tr><tr><td align="left" rowspan="1" colspan="1">Time to inclusion (days)</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">9&#x000b7;8 &#x000b1; 10&#x000b7;7</td></tr><tr><td align="left" colspan="2" rowspan="1">Admission diagnosis</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Cardiac</td><td align="char" char="(" rowspan="1" colspan="1">18 (27%)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Cardiopulmonary resuscitation</td><td align="char" char="(" rowspan="1" colspan="1">21 (32%)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Infection</td><td align="char" char="(" rowspan="1" colspan="1">10 (15%)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Respiratory disease</td><td align="char" char="(" rowspan="1" colspan="1">10 (15%)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">gastrointestinal disease</td><td align="char" char="(" rowspan="1" colspan="1">1 (2%)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">thromboembolism (i.e. Stroke, Pulmonary embolism)</td><td align="char" char="(" rowspan="1" colspan="1">3 (5%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Others</td><td align="char" char="(" rowspan="1" colspan="1">3 (5%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Catecholamine treatment <italic>n</italic> (%)</td><td align="char" char="(" rowspan="1" colspan="1">20 (30%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Continuous veno&#x02010;venous hemodiafiltration <italic>n</italic> (%)</td><td align="char" char="(" rowspan="1" colspan="1">12 (18%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Nonsteroidal anti&#x02010;inflammatory drugs</td><td align="char" char="(" rowspan="1" colspan="1">21 (32%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Lactate (mM)</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">1&#x000b7;0 &#x000b1; 0&#x000b7;4</td></tr></tbody></table><table-wrap-foot><fn id="eci12771-note-0001"><label>a</label><p>Presented are means &#x000b1; standard deviations and numbers (%) of all 66 patients.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd</copyright-holder></permissions></table-wrap><sec id="eci12771-sec-0016"><title>Platelet aggregation</title><p>Fifty&#x02010;six of 66 patients (85%, 95% CI: 74&#x02013;93%) had HTPR according to the defined criteria: &#x0003e; 30 U in the AA&#x02010;induced platelet aggregation (Fig. <xref rid="eci12771-fig-0002" ref-type="fig">2</xref>). Continued intake of 100 mg enteric&#x02010;coated ASA transiently decreased platelet aggregation after 2 h (<italic>P</italic> = 0&#x000b7;038 vs. 0 h). Aggregation was similar between 0 and 24 h.</p><fig fig-type="Figure" xml:lang="en" id="eci12771-fig-0002" orientation="portrait" position="float"><label>Figure 2</label><caption><p>Arachidonic acid&#x02010; and ADP&#x02010;induced platelet aggregation using whole&#x02010;blood aggregometry. Panel (a) Arachidonic acid&#x02010;induced platelet aggregation during screening, individual values (dots), median and quartiles (horizontal lines) Panel (b) Relative changes in arachidonic acid&#x02010;induced platelet aggregation at baseline and after 100 mg intravenous, 100 mg enteric&#x02010;coated acetylsalicylic acid (ASA) bid or 81 mg chewable ASA, presented are medians &#x000b1; interquartile ranges; 0 h or D1 0 h = before intake or infusion of Aspirin, 1 h = 1 h after intake or infusion, 2 h = 2 h after intake or infusion, 4 h = 4 h after intake or infusion, 24 h = 24 h after intake or infusion of ASA.</p></caption><graphic id="nlm-graphic-3" xlink:href="ECI-47-504-g002"/></fig><p>Platelet aggregation between the three groups did not differ significantly. However, platelet aggregation changed significantly over time (<italic>P</italic> &#x0003c; 0&#x000b7;001). This indicates the impact of each intervention on platelet aggregation during 24 h.</p><p>Infusion of 100 mg ASA i.v. and intake of 81 mg chewable ASA significantly reduced AA&#x02010;induced platelet aggregation (<italic>P</italic> = 0&#x000b7;007 and <italic>P</italic> = 0&#x000b7;001, univariate analysis, Table <xref rid="eci12771-sup-0003" ref-type="supplementary-material">S1</xref>). However, intake of 100 mg enteric&#x02010;coated ASA bid did not significantly reduce platelet aggregation in univariate analysis; numerically MEA values after 24 h were the lowest of all groups (Table <xref rid="eci12771-sup-0003" ref-type="supplementary-material">S1</xref>). The impact of the alternative treatments on HTPR is presented in Table <xref rid="eci12771-sup-0005" ref-type="supplementary-material">S3</xref>.</p><p>Results of AA&#x02010; and ADP&#x02010;induced platelet aggregation correlated well at baseline (<italic>r</italic> = 0&#x000b7;64 <italic>P</italic> &#x0003c; 0&#x000b7;001). Both tests also correlated reasonably well with the platelet count (AA: <italic>r</italic> = 0&#x000b7;49, <italic>P</italic> &#x0003c; 0&#x000b7;001; ADP: <italic>r</italic> = 0&#x000b7;7, <italic>P</italic> &#x0003c; 0&#x000b7;001). However, platelet aggregation did not correlate (not significant or <italic>r</italic> &#x0003c; 0&#x000b7;3) with haemoglobin level, fibrinogen, serum C&#x02010;reactive protein level or disease scores (SOFA, SAPSIII).</p></sec><sec id="eci12771-sec-0017"><title>Platelet function under high shear rates</title><p>Twenty&#x02010;nine of 66 patients (44%, 95% CI: 32&#x02013;57%) were diagnosed with HTPR according to the defined criteria: closure time &#x0003c; 193 s for epinephrine&#x02010;coated cartridges.</p><p>PFA&#x02010;EPI and PFA&#x02010;ADP showed only a weak correlation at baseline (<italic>r</italic> = 0&#x000b7;34, <italic>P</italic> = 0&#x000b7;005). PFA&#x02010;ADP correlated weakly with platelet count (<italic>r</italic> = 0&#x000b7;37, <italic>P</italic> = 0&#x000b7;003). PFA&#x02010;EPI or PFA&#x02010;ADP did not correlate (not significant or <italic>r</italic> &#x0003c; 0&#x000b7;3) with haemoglobin level, leucocyte count, fibrinogen, C&#x02010;reactive protein level or disease scores (SOFA, SAPSIII).</p></sec><sec id="eci12771-sec-0018"><title>TXB2 results</title><p>At baseline, before the next daily dose of 100 mg enteric&#x02010;coated ASA, median TXB2 levels were 0&#x000b7;35 (quartiles: 0&#x000b7;07&#x02013;0&#x000b7;94) ng/mL. Intake of 100 mg enteric&#x02010;coated ASA reduced TXB2 levels to 0&#x000b7;12 (0&#x000b7;05&#x02013;0&#x000b7;33) ng/mL after 2 h <italic>P</italic> &#x0003c; 0&#x000b7;001 vs. 0 h), which almost returned to baseline 0&#x000b7;25 (0&#x000b7;08&#x02013;0&#x000b7;82) ng/mL 24 h thereafter (Fig. <xref rid="eci12771-fig-0003" ref-type="fig">3</xref>).</p><fig fig-type="Figure" xml:lang="en" id="eci12771-fig-0003" orientation="portrait" position="float"><label>Figure 3</label><caption><p>Plasma thromboxane B2 (<styled-content style="fixed-case">TXB</styled-content>2) concentrations in critically ill patients treated with 100 mg enteric&#x02010;coated acetylsalicylic acid (<styled-content style="fixed-case">ASA</styled-content>) (panel a), 100 mg intravenous <styled-content style="fixed-case">ASA</styled-content> (panel b, <italic>n</italic> = 10), 100 mg enteric&#x02010;coated <styled-content style="fixed-case">ASA</styled-content> bid (panel c, <italic>n</italic> = 10) and 81 mg enteric&#x02010;coated <styled-content style="fixed-case">ASA</styled-content> (panel d, <italic>n</italic> = 10). Presented are medians &#x000b1; interquartile ranges.</p></caption><graphic id="nlm-graphic-5" xlink:href="ECI-47-504-g003"/></fig><p>In multivariate testing, there was no significant difference between the three treatment groups. Only intake of 100 mg enteric&#x02010;coated ASA bid reduced TXB2 levels significantly over time (univariate analysis, <italic>P</italic> = 0&#x000b7;048).</p><p>Infusion of ASA reduced TXB2 levels from a baseline 0&#x000b7;35 (0&#x000b7;25&#x02013;1&#x000b7;38) ng/mL to median 0&#x000b7;07&#x02013;0&#x000b7;1 ng/mL for the next 24 h (pairwise comparisons, <italic>P</italic> = 0&#x000b7;007, <italic>P</italic> = 0&#x000b7;005, <italic>P</italic> = 0&#x000b7;005, <italic>P</italic> = 0&#x000b7;017, for baseline vs. 1 h, 2 h, 4 h, 24 h, Fig. <xref rid="eci12771-fig-0003" ref-type="fig">3</xref>). Intake of 100 mg enteric&#x02010;coated ASA bid decreased TXB2 levels from median 0&#x000b7;4 (0&#x000b7;24&#x02013;0&#x000b7;92) ng/mL at baseline to median 0&#x000b7;09&#x02013;0&#x000b7;18 ng/mL (<italic>P</italic> = 0&#x000b7;021, <italic>P</italic> = 0&#x000b7;13, <italic>P</italic> = 0&#x000b7;026, <italic>P</italic> = 0&#x000b7;05, for baseline vs. 1 h, 2 h, 4 h, 24 h) for the next 24 h. Treatment with 81 mg chewable ASA tablets reduced TXB2 levels from median 0&#x000b7;6 ng/mL (0&#x000b7;08&#x02013;1&#x000b7;65 ng/mL) at baseline to median 0&#x000b7;25&#x02013;0&#x000b7;46 ng/mL (<italic>P</italic> = 0&#x000b7;005, <italic>P</italic> = 0&#x000b7;005, <italic>P</italic> = 0&#x000b7;09, <italic>P</italic> = 0&#x000b7;88, for baseline vs. 1 h, 2 h, 4 h, 24 h) in the next 24 h.</p><p>We recorded the intake of nonsteroidal anti&#x02010;inflammatory drugs, which was equally distributed between the randomized groups (2 or 3 per group) and had no apparent effect on TXB2 measurements.</p></sec><sec id="eci12771-sec-0019"><title>Pharmacokinetics</title><p>There were no significant differences between the three treatment groups in multivariate analysis, although drug concentrations changed significantly over time (<italic>P</italic> &#x0003c; 0&#x000b7;001).</p><p>Peak concentrations of ASA (<italic>P</italic> = 0&#x000b7;013) and salicylic acid (<italic>P</italic> = 0&#x000b7;005) were higher after infusion of 100 mg ASA compared to 100 mg enteric&#x02010;coated ASA and maximum salicylic acid levels compared to 81 mg chewable ASA (<italic>P</italic> = 0&#x000b7;023). Plasma concentrations of ASA and salicylic acid were similar between 81 mg chewable ASA and 100 mg enteric&#x02010;coated ASA. Plasma concentrations of ASA and salicylic acid levels are presented in Table <xref rid="eci12771-sup-0004" ref-type="supplementary-material">S2</xref> and Fig. <xref rid="eci12771-fig-0004" ref-type="fig">4</xref>.</p><fig fig-type="Figure" xml:lang="en" id="eci12771-fig-0004" orientation="portrait" position="float"><label>Figure 4</label><caption><p>Plasma concentrations of acetylsalicylic acid (ASA) (&#x025a1;) and salicylic acid (&#x025a0;) of 100 mg enteric&#x02010;coated <styled-content style="fixed-case">ASA</styled-content> (left upper quadrant, <italic>n</italic> = 66), 100 mg enteric&#x02010;coated <styled-content style="fixed-case">ASA</styled-content> bid (right upper quadrant, <italic>n</italic> = 10), 100 mg <styled-content style="fixed-case">ASA</styled-content> i.v. (left lower quadrant, <italic>n</italic> = 10) and 81 mg chewable <styled-content style="fixed-case">ASA</styled-content> (right lower quadrant, <italic>n</italic> = 10). Medians &#x000b1; interquartile ranges are presented.</p></caption><graphic id="nlm-graphic-7" xlink:href="ECI-47-504-g004"/></fig><p>The coefficient of variation of salicylic acid concentrations was 80% 2 h after administration of 100 mg enteric&#x02010;coated ASA, 70% after intake of 81 mg chewable ASA and 45% after infusion of 100 mg ASA.</p><p>The <italic>T</italic>
<sub>1/2</sub> of salicylic after infusion of ASA was approximately 102 and 96 min after intake of chewable ASA. The <italic>T</italic>
<sub>1/2</sub> of enteric&#x02010;coated ASA could not be determined because of slow absorption.</p></sec><sec id="eci12771-sec-0020"><title>Adverse events</title><p>The trial lasted 24 h in 36 patients and 48 h in 30 patients. No drug&#x02010;related adverse events occurred in the interventional trial. Two patients experienced major bleeding and one patient acute cerebral infarction in the noninterventional study. One patient died during the noninterventional trial.</p></sec></sec><sec id="eci12771-sec-0021"><title>Discussion</title><p>Our main findings are that (i) the prevalence of HTPR is much higher in critically ill patients than reported previously <xref rid="eci12771-bib-0007" ref-type="ref">7</xref>, <xref rid="eci12771-bib-0008" ref-type="ref">8</xref>, (ii) the plasma concentrations of ASA and salicylic acid are highly variable, and (iii) TXB2 levels, although suppressed to a large extent, show a remaining potentially pathophysiologically relevant background activity in many patients.</p><p>In patients with acute myocardial infarction with chronic ASA therapy, TXB2 levels were 0&#x000b7;09 ng/mL (quartiles: 0&#x000b7;03&#x02013;0&#x000b7;43) <xref rid="eci12771-bib-0024" ref-type="ref">24</xref>. Additional infusion of 250 mg ASA decreased TXB2 levels to 0&#x000b7;04 ng/mL (0&#x000b7;01&#x02013;0&#x000b7;04 ng/mL) and significantly lowered HTPR <xref rid="eci12771-bib-0024" ref-type="ref">24</xref>. This indicates that thromboxane levels &#x0003c; 0&#x000b7;43 ng/mL are still relevant. Median TXB2 concentrations in our population were 0&#x000b7;35 ng/mL and thus ~fourfold higher <xref rid="eci12771-bib-0024" ref-type="ref">24</xref>. Furthermore, a discrepancy between the measurement of serum TXB2 <italic>ex vivo</italic> and thromboxane generation <italic>in vivo</italic>, assessed by excretion of 2,3&#x02010;dinor&#x02010;thromboxane, was reported <xref rid="eci12771-bib-0025" ref-type="ref">25</xref>. In healthy volunteers, a 94 &#x000b1; 1% inhibition of serum TXB2 <italic>ex vivo</italic> by intake of aspirin only translated to a 28 &#x000b1; 8% inhibition of urinary 2,3&#x02010;dinor&#x02010;thromboxane <italic>in vivo</italic>
<xref rid="eci12771-bib-0025" ref-type="ref">25</xref>. However, the <italic>in vivo</italic> generation of thromboxane was reduced by increasing the degree of serum TXB2 inhibition to &#x02265; 95% <xref rid="eci12771-bib-0025" ref-type="ref">25</xref>. Thus, &#x02265; 95% inhibition of TXB2 could be necessary to achieve sufficient platelet inhibition.</p><p>Surprisingly, even after the infusion of ASA, TXB2 was not fully suppressed. Although thromboxane is generally regarded as COX&#x02010;1 dependent <xref rid="eci12771-bib-0026" ref-type="ref">26</xref>, other sources of thromboxane generation have been reported <xref rid="eci12771-bib-0027" ref-type="ref">27</xref>, <xref rid="eci12771-bib-0028" ref-type="ref">28</xref> including COX&#x02010;2&#x02010;dependent thromboxane generation during inflammatory states <xref rid="eci12771-bib-0029" ref-type="ref">29</xref> or in reticulated platelets <xref rid="eci12771-bib-0030" ref-type="ref">30</xref>. Moreover, nucleated cells may regenerate COX&#x02010;1 <xref rid="eci12771-bib-0031" ref-type="ref">31</xref>. Treatment of septic patients with ibuprofen had beneficial effects on metabolic biomarkers, such as oxygen consumption or blood lactate levels, and it reduced the excretion of thromboxane metabolites, but the mortality benefit did not reach significance (37% vs. 40%) <xref rid="eci12771-bib-0032" ref-type="ref">32</xref>. However, this trial included 455 patients and was only powered to detect a 35% difference in mortality between groups. The observed difference would have required a sample size of approximately &#x0003e; 8&#x000b7;000 patients.</p><p>We detected a surprisingly high HTPR rate. Most studies report a HTPR rate of approximately 20% using MEA <xref rid="eci12771-bib-0033" ref-type="ref">33</xref>. In patients undergoing haemodialysis, 50% of patients had HTPR <xref rid="eci12771-bib-0034" ref-type="ref">34</xref>. Interestingly, in patients undergoing coronary artery bypass&#x02010;graft surgery, the HTPR rate increased postoperatively <xref rid="eci12771-bib-0017" ref-type="ref">17</xref>, <xref rid="eci12771-bib-0035" ref-type="ref">35</xref>. Various factors, such as platelet count, haematocrit, leucocyte count, red blood cell count, C&#x02010;reactive protein levels or fibrinogen, correlated with the results of MEA <xref rid="eci12771-bib-0016" ref-type="ref">16</xref>, <xref rid="eci12771-bib-0036" ref-type="ref">36</xref>. In our trial, only platelet count correlated well with MEA results. However, our population was not homogenous and probably too small to find such associations. The extraordinary high rate of HTPR in our trial may be explained by the residual thromboxane activity, a higher platelet turnover and possibly an impaired absorption after oral ASA treatment.</p><p>The PFA&#x02010;100 classified 44% of patients with HTPR, which is in line with other reports <xref rid="eci12771-bib-0037" ref-type="ref">37</xref>. The closure time detected by this system is affected by haematocrit, platelet count and the von Willebrand factor activity <xref rid="eci12771-bib-0038" ref-type="ref">38</xref>. There is limited knowledge on its applicability in critically ill patients. Platelet function measurements with CADP cartridges showed a generalized platelet defect in 24 of 66 patients. In these patients, detection of HTPR may not have been possible, and the prevalence of HTPR may therefore be underestimated.</p><p>Crushing and/or dissolving tablets affects the pharmacokinetics with a shorter <italic>T</italic>
<sub>max</sub> compared to intake of whole tablets <xref rid="eci12771-bib-0039" ref-type="ref">39</xref>. Individual plasma concentration&#x02013;time curves after intake of oral ASA formulations suggest highly variable absorption patterns in critically ill patients (Figure <xref rid="eci12771-sup-0002" ref-type="supplementary-material">S1</xref>), which is also reflected by high coefficients of variation for salicylic acid levels ranging between 45% and 80% 2 h after intake. In some patients, drug absorption seems to be delayed possibly due to reduced gastrointestinal motility. Compared to healthy volunteers, the salicylic acid concentrations after intake of ASA were markedly lower in our patients, regardless of the formulation <xref rid="eci12771-bib-0018" ref-type="ref">18</xref>, <xref rid="eci12771-bib-0039" ref-type="ref">39</xref>. Thus, absorption of orally administered drugs is severely impaired in some critically ill patients. Therefore, especially in high&#x02010;risk patients, intravenous formulations should be considered to optimize bioavailability.</p><p>The half&#x02010;life of salicylic acid on day 2 for i.v. and chewable ASA was approximately 100 min. This is in line with other studies <xref rid="eci12771-bib-0018" ref-type="ref">18</xref> and demonstrates that metabolism and excretion of ASA is not altered in ICU patients.</p><p>Taken together, these data indicate that in order to ensure adequate platelet inhibition in critically ill patients, clinicians should consider using intravenous formulations, and/or possibly two daily doses. Treatment with oral formulations bears the risk of insufficient absorption of ASA and consequently reduced antiplatelet effects.</p><sec id="eci12771-sec-0022"><title>Limitations</title><p>The included population was quite inhomogeneous. However, all patients were treated with ASA and we aimed to define the prevalence of HTPR in ICU patients regardless of the underlying disease. Secondly, this study was powered to show improvements in platelet function assays by alternative treatments and to show the significantly increased rate of HTPR in critically ill patients, but not to assess the clinical impact of HTPR in these patients. Thirdly, we were only able to conduct sparse pharmacokinetic analyses due to the severe condition of patients. Finally, this trial did not interfere with regular treatment of patients and the intake of nonsteroidal antiphlogistic drugs was therefore not forbidden.</p></sec></sec><sec id="eci12771-sec-0023"><title>Conclusion</title><p>The measured TXB2 levels and the high HTPR rate suggest insufficient platelet inhibition by ASA in critically ill patients. This may in part be caused by the impaired absorption of orally administered drugs or by COX&#x02010;2&#x02010;dependent thromboxane generation during systemic inflammation. Intravenous formulations reduce the substantial variability of ASA/salicylic acid concentrations and could be a better choice for high&#x02010;risk patients in the ICU.</p></sec><sec id="eci12771-sec-0025"><title>Disclosures</title><p>The authors report no conflict of interests.</p></sec><sec id="eci12771-sec-0026"><title>Sources of funding</title><p>The Austrian Science Funds (FWF, grant number SFB54P04) funded this work. The funding source played no role in study design, in the collection, analysis or interpretation of data, in the writing of the report, and in the decision to submit the article for publication.</p></sec><sec id="eci12771-sec-0027"><title>Authors&#x02019; contribution</title><p>CS and BJ designed the trial. All authors were involved in the conduct of the trial and in the acquisition of data. EH and BR measured drug levels. All authors were involved in the analysis and interpretation of the trial. CS and BJ drafted the manuscript. All authors critically revised the manuscript and approved the final version for publication.</p></sec><sec id="eci12771-sec-0028"><title>Address</title><p>Department of Clinical Pharmacology, Medical University of Vienna, W&#x000e4;hringer G&#x000fc;rtel 18&#x02010;20, 1090 Vienna, Austria (C. Schoergenhofer, E.&#x02010;L. Hobl, M. Schwameis, G. Gelbenegger, B. Jilma); Department of Internal Medicine I, Oncology &#x00026; Hematology Medical University of Vienna, W&#x000e4;hringer G&#x000fc;rtel 18&#x02010;20, 1090 Vienna, Austria (T. Staudinger); Department of Internal Medicine II, Cardiology Medical University of Vienna, W&#x000e4;hringer G&#x000fc;rtel 18&#x02010;20, 1090 Vienna, Austria (G. Heinz, W. S. Speidl, I. Lang); Department of Internal Medicine III, Gastroenterology &#x00026; Hepatology, Medical University of Vienna, W&#x000e4;hringer G&#x000fc;rtel 18&#x02010;20, 1090 Vienna, Austria (C. Zauner); Clinical Institute of Laboratory Medicine, Forensic Toxicology Unit, Medical University of Vienna, W&#x000e4;hringer G&#x000fc;rtel, 18&#x02010;20, 1090 Vienna, Austria (B. Reiter).</p></sec><sec sec-type="supplementary-material"><title>Supporting information</title><supplementary-material content-type="local-data" id="eci12771-sup-0001"><caption><p>
<bold>Appendix S1.</bold> Methods</p></caption><media xlink:href="ECI-47-504-s001.docx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="eci12771-sup-0002"><caption><p>
<bold>Figure S1.</bold> Individual plasma concentrations of acetylsalicylic acid and salicylic acid in ng/mL after intake of 100 mg enteric&#x02010;coated acetylsalicylic acid (left upper panel), 81 mg chewable acetylsalicylic acid (right upper panel), 100 mg enteric&#x02010;coated acetylsalicylic acid (left lower panel) and infusion of 100 mg acetylsalicylic acid (right lower panel).</p></caption><media xlink:href="ECI-47-504-s002.jpg"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="eci12771-sup-0003"><caption><p>
<bold>Table S1.</bold> Arachidonic Acid&#x02010;induced platelet aggregation using whole blood aggregometry after alternative ASA treatments.</p></caption><media xlink:href="ECI-47-504-s003.docx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="eci12771-sup-0004"><caption><p>
<bold>Table S2.</bold> Acetylsalicylic acid (ASA) and Salicylic acid (SA) plasma concentrations after different ASA treatments.</p></caption><media xlink:href="ECI-47-504-s004.docx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="eci12771-sup-0005"><caption><p>
<bold>Table S3.</bold> HTPR assessed on day 1 and at day 2 24 h.</p></caption><media xlink:href="ECI-47-504-s005.docx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ack id="eci12771-sec-0024"><title>Acknowledgements</title><p>The authors would like to thank Sabine Schranz, Karin Petroczi and Christa Drucker for their invaluable help throughout the trial.</p></ack><ref-list content-type="cited-references" id="eci12771-bibl-0001"><title>References</title><ref id="eci12771-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="eci12771-cit-0001">
<string-name>
<surname>Bansilal</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Castellano</surname>
<given-names>JM</given-names>
</string-name>, <string-name>
<surname>Fuster</surname>
<given-names>V</given-names>
</string-name>. <article-title>Global burden of CVD: focus on secondary prevention of cardiovascular disease</article-title>. <source>Int J Cardiol</source>
<year>2015</year>;<volume>201</volume>(<issue>Suppl 1</issue>):<fpage>S1</fpage>&#x02013;<lpage>7</lpage>.<pub-id pub-id-type="pmid">26747389</pub-id></mixed-citation></ref><ref id="eci12771-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="eci12771-cit-0002">
<string-name>
<surname>Wu</surname>
<given-names>IC</given-names>
</string-name>, <string-name>
<surname>Hsieh</surname>
<given-names>HM</given-names>
</string-name>, <string-name>
<surname>Yu</surname>
<given-names>FJ</given-names>
</string-name>, <string-name>
<surname>Wu</surname>
<given-names>MC</given-names>
</string-name>, <string-name>
<surname>Wu</surname>
<given-names>TS</given-names>
</string-name>, <string-name>
<surname>Wu</surname>
<given-names>MT</given-names>
</string-name>. <article-title>A long&#x02010;term risk&#x02010;benefit analysis of low&#x02010;dose aspirin in primary prevention</article-title>. <source>Eur J Clin Invest</source>
<year>2016</year>;<volume>46</volume>:<fpage>130</fpage>&#x02013;<lpage>40</lpage>.<pub-id pub-id-type="pmid">26640116</pub-id></mixed-citation></ref><ref id="eci12771-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="eci12771-cit-0003">
<string-name>
<surname>Winning</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Neumann</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Kohl</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Claus</surname>
<given-names>RA</given-names>
</string-name>, <string-name>
<surname>Reinhart</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Bauer</surname>
<given-names>M</given-names>
</string-name>
<italic>et al</italic>
<article-title>Antiplatelet drugs and outcome in mixed admissions to an intensive care unit</article-title>. <source>Crit Care Med</source>
<year>2010</year>;<volume>38</volume>:<fpage>32</fpage>&#x02013;<lpage>7</lpage>.<pub-id pub-id-type="pmid">19770746</pub-id></mixed-citation></ref><ref id="eci12771-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="eci12771-cit-0004">
<string-name>
<surname>Osthoff</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Sidler</surname>
<given-names>JA</given-names>
</string-name>, <string-name>
<surname>Lakatos</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Frei</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Dangel</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Weisser</surname>
<given-names>M</given-names>
</string-name>
<italic>et al</italic>
<article-title>Low&#x02010;dose acetylsalicylic acid treatment and impact on short&#x02010;term mortality in <italic>Staphylococcus aureus</italic> bloodstream infection: a propensity score&#x02010;matched cohort study</article-title>. <source>Crit Care Med</source>
<year>2016</year>;<volume>44</volume>:<fpage>773</fpage>&#x02013;<lpage>81</lpage>.<pub-id pub-id-type="pmid">26741577</pub-id></mixed-citation></ref><ref id="eci12771-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="eci12771-cit-0005">
<string-name>
<surname>Falcone</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Russo</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Farcomeni</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Pieralli</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Vannucchi</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Vullo</surname>
<given-names>V</given-names>
</string-name>
<italic>et al</italic>
<article-title>Septic shock from community&#x02010;onset pneumonia: is there a role for aspirin plus macrolides combination?</article-title>
<source>Intensive Care Med</source>
<year>2016</year>;<volume>42</volume>:<fpage>301</fpage>&#x02013;<lpage>2</lpage>.<pub-id pub-id-type="pmid">26585791</pub-id></mixed-citation></ref><ref id="eci12771-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="eci12771-cit-0006">
<string-name>
<surname>Spiliopoulos</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Pastromas</surname>
<given-names>G</given-names>
</string-name>. <article-title>Current status of high on&#x02010;treatment platelet reactivity in patients with coronary or peripheral arterial disease: mechanisms, evaluation and clinical implications</article-title>. <source>World J Cardiol</source>
<year>2015</year>;<volume>7</volume>:<fpage>912</fpage>&#x02013;<lpage>21</lpage>.<pub-id pub-id-type="pmid">26730297</pub-id></mixed-citation></ref><ref id="eci12771-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="eci12771-cit-0007">
<string-name>
<surname>Krasopoulos</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Brister</surname>
<given-names>SJ</given-names>
</string-name>, <string-name>
<surname>Beattie</surname>
<given-names>WS</given-names>
</string-name>, <string-name>
<surname>Buchanan</surname>
<given-names>MR</given-names>
</string-name>. <article-title>Aspirin &#x0201c;resistance&#x0201d; and risk of cardiovascular morbidity: systematic review and meta&#x02010;analysis</article-title>. <source>BMJ</source>
<year>2008</year>;<volume>336</volume>:<fpage>195</fpage>&#x02013;<lpage>8</lpage>.<pub-id pub-id-type="pmid">18202034</pub-id></mixed-citation></ref><ref id="eci12771-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="eci12771-cit-0008">
<string-name>
<surname>Neubauer</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Kaiser</surname>
<given-names>AF</given-names>
</string-name>, <string-name>
<surname>Endres</surname>
<given-names>HG</given-names>
</string-name>, <string-name>
<surname>Kruger</surname>
<given-names>JC</given-names>
</string-name>, <string-name>
<surname>Engelhardt</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Lask</surname>
<given-names>S</given-names>
</string-name>
<italic>et al</italic>
<article-title>Tailored antiplatelet therapy can overcome clopidogrel and aspirin resistance&#x02013;the BOchum CLopidogrel and Aspirin Plan (BOCLA&#x02010;Plan) to improve antiplatelet therapy</article-title>. <source>BMC Med</source>
<year>2011</year>;<volume>9</volume>:<fpage>3</fpage>.<pub-id pub-id-type="pmid">21226927</pub-id></mixed-citation></ref><ref id="eci12771-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="eci12771-cit-0009">
<string-name>
<surname>Deitchman</surname>
<given-names>AN</given-names>
</string-name>, <string-name>
<surname>Derendorf</surname>
<given-names>H</given-names>
</string-name>. <article-title>Measuring drug distribution in the critically ill patient</article-title>. <source>Adv Drug Deliv Rev</source>
<year>2014</year>;<volume>77</volume>:<fpage>22</fpage>&#x02013;<lpage>6</lpage>.<pub-id pub-id-type="pmid">25194997</pub-id></mixed-citation></ref><ref id="eci12771-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="eci12771-cit-0010">
<string-name>
<surname>Kar</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Jones</surname>
<given-names>KL</given-names>
</string-name>, <string-name>
<surname>Horowitz</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Chapman</surname>
<given-names>MJ</given-names>
</string-name>, <string-name>
<surname>Deane</surname>
<given-names>AM</given-names>
</string-name>. <article-title>Measurement of gastric emptying in the critically ill</article-title>. <source>Clin Nutr</source>
<year>2015</year>;<volume>34</volume>:<fpage>557</fpage>&#x02013;<lpage>64</lpage>.<pub-id pub-id-type="pmid">25491245</pub-id></mixed-citation></ref><ref id="eci12771-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="eci12771-cit-0011">
<string-name>
<surname>Roberts</surname>
<given-names>DJ</given-names>
</string-name>, <string-name>
<surname>Hall</surname>
<given-names>RI</given-names>
</string-name>. <article-title>Drug absorption, distribution, metabolism and excretion considerations in critically ill adults</article-title>. <source>Expert Opin Drug Metab Toxicol</source>
<year>2013</year>;<volume>9</volume>:<fpage>1067</fpage>&#x02013;<lpage>84</lpage>.<pub-id pub-id-type="pmid">23682923</pub-id></mixed-citation></ref><ref id="eci12771-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="eci12771-cit-0012">
<string-name>
<surname>Freynhofer</surname>
<given-names>MK</given-names>
</string-name>, <string-name>
<surname>Gruber</surname>
<given-names>SC</given-names>
</string-name>, <string-name>
<surname>Grove</surname>
<given-names>EL</given-names>
</string-name>, <string-name>
<surname>Weiss</surname>
<given-names>TW</given-names>
</string-name>, <string-name>
<surname>Wojta</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Huber</surname>
<given-names>K</given-names>
</string-name>. <article-title>Antiplatelet drugs in patients with enhanced platelet turnover: biomarkers versus platelet function testing</article-title>. <source>Thromb Haemost</source>
<year>2015</year>;<volume>114</volume>:<fpage>459</fpage>&#x02013;<lpage>68</lpage>.<pub-id pub-id-type="pmid">26272640</pub-id></mixed-citation></ref><ref id="eci12771-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="eci12771-cit-0013">
<string-name>
<surname>Simera</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Moher</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Hoey</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Schulz</surname>
<given-names>KF</given-names>
</string-name>, <string-name>
<surname>Altman</surname>
<given-names>DG</given-names>
</string-name>. <article-title>A catalogue of reporting guidelines for health research</article-title>. <source>Eur J Clin Invest</source>
<year>2010</year>;<volume>40</volume>:<fpage>35</fpage>&#x02013;<lpage>53</lpage>.<pub-id pub-id-type="pmid">20055895</pub-id></mixed-citation></ref><ref id="eci12771-bib-0014"><label>14</label><mixed-citation publication-type="journal" id="eci12771-cit-0014">
<string-name>
<surname>Le Quellec</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Bordet</surname>
<given-names>JC</given-names>
</string-name>, <string-name>
<surname>Negrier</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Dargaud</surname>
<given-names>Y</given-names>
</string-name>. <article-title>Comparison of current platelet functional tests for the assessment of aspirin and clopidogrel response. A review of the literature</article-title>. <source>Thromb Haemost</source>
<year>2016</year>;<volume>116</volume>:<fpage>638</fpage>&#x02013;<lpage>50</lpage>.<pub-id pub-id-type="pmid">27440202</pub-id></mixed-citation></ref><ref id="eci12771-bib-0015"><label>15</label><mixed-citation publication-type="journal" id="eci12771-cit-0015">
<string-name>
<surname>Siller&#x02010;Matula</surname>
<given-names>JM</given-names>
</string-name>, <string-name>
<surname>Delle&#x02010;Karth</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Christ</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Neunteufl</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Maurer</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Huber</surname>
<given-names>K</given-names>
</string-name>
<italic>et al</italic>
<article-title>Dual non&#x02010;responsiveness to antiplatelet treatment is a stronger predictor of cardiac adverse events than isolated non&#x02010;responsiveness to clopidogrel or aspirin</article-title>. <source>Int J Cardiol</source>
<year>2013</year>;<volume>167</volume>:<fpage>430</fpage>&#x02013;<lpage>5</lpage>.<pub-id pub-id-type="pmid">22305813</pub-id></mixed-citation></ref><ref id="eci12771-bib-0016"><label>16</label><mixed-citation publication-type="journal" id="eci12771-cit-0016">
<string-name>
<surname>Jastrzebska</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Chelstowski</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Wodecka</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Siennicka</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Clark</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Nowacki</surname>
<given-names>P</given-names>
</string-name>. <article-title>Factors influencing multiplate whole blood impedance platelet aggregometry measurements, during aspirin treatment in acute ischemic stroke: a pilot study</article-title>. <source>Blood Coagul Fibrinolysis</source>
<year>2013</year>;<volume>24</volume>:<fpage>830</fpage>&#x02013;<lpage>8</lpage>.<pub-id pub-id-type="pmid">24071649</pub-id></mixed-citation></ref><ref id="eci12771-bib-0017"><label>17</label><mixed-citation publication-type="journal" id="eci12771-cit-0017">
<string-name>
<surname>Bolliger</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Filipovic</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Matt</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Tanaka</surname>
<given-names>KA</given-names>
</string-name>, <string-name>
<surname>Gregor</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Zenklusen</surname>
<given-names>U</given-names>
</string-name>
<italic>et al</italic>
<article-title>Reduced aspirin responsiveness as assessed by impedance aggregometry is not associated with adverse outcome after cardiac surgery in a small low&#x02010;risk cohort</article-title>. <source>Platelets</source>
<year>2016</year>;<volume>27</volume>:<fpage>254</fpage>&#x02013;<lpage>61</lpage>.<pub-id pub-id-type="pmid">26367099</pub-id></mixed-citation></ref><ref id="eci12771-bib-0018"><label>18</label><mixed-citation publication-type="journal" id="eci12771-cit-0018">
<string-name>
<surname>Hobl</surname>
<given-names>EL</given-names>
</string-name>, <string-name>
<surname>Schmid</surname>
<given-names>RW</given-names>
</string-name>, <string-name>
<surname>Stimpfl</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Ebner</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Jilma</surname>
<given-names>B</given-names>
</string-name>. <article-title>Absorption kinetics of low&#x02010;dose chewable aspirin&#x02013;implications for acute coronary syndromes</article-title>. <source>Eur J Clin Invest</source>
<year>2015</year>;<volume>45</volume>:<fpage>13</fpage>&#x02013;<lpage>7</lpage>.<pub-id pub-id-type="pmid">25402445</pub-id></mixed-citation></ref><ref id="eci12771-bib-0019"><label>19</label><mixed-citation publication-type="journal" id="eci12771-cit-0019">
<string-name>
<surname>Jilma</surname>
<given-names>B</given-names>
</string-name>. <article-title>Platelet function analyzer (PFA&#x02010;100): a tool to quantify congenital or acquired platelet dysfunction</article-title>. <source>J Lab Clin Med</source>
<year>2001</year>;<volume>138</volume>:<fpage>152</fpage>&#x02013;<lpage>63</lpage>.<pub-id pub-id-type="pmid">11528368</pub-id></mixed-citation></ref><ref id="eci12771-bib-0020"><label>20</label><mixed-citation publication-type="journal" id="eci12771-cit-0020">
<string-name>
<surname>Jilma&#x02010;Stohlawetz</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Hergovich</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Homoncik</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Dzirlo</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Horvath</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Janisiw</surname>
<given-names>M</given-names>
</string-name>
<italic>et al</italic>
<article-title>Impaired platelet function among platelet donors</article-title>. <source>Thromb Haemost</source>
<year>2001</year>;<volume>86</volume>:<fpage>880</fpage>&#x02013;<lpage>6</lpage>.<pub-id pub-id-type="pmid">11583322</pub-id></mixed-citation></ref><ref id="eci12771-bib-0021"><label>21</label><mixed-citation publication-type="journal" id="eci12771-cit-0021">
<string-name>
<surname>Bae</surname>
<given-names>SK</given-names>
</string-name>, <string-name>
<surname>Seo</surname>
<given-names>KA</given-names>
</string-name>, <string-name>
<surname>Jung</surname>
<given-names>EJ</given-names>
</string-name>, <string-name>
<surname>Kim</surname>
<given-names>HS</given-names>
</string-name>, <string-name>
<surname>Yeo</surname>
<given-names>CW</given-names>
</string-name>, <string-name>
<surname>Shon</surname>
<given-names>JH</given-names>
</string-name>
<italic>et al</italic>
<article-title>Determination of acetylsalicylic acid and its major metabolite, salicylic acid, in human plasma using liquid chromatography&#x02010;tandem mass spectrometry: application to pharmacokinetic study of Astrix in Korean healthy volunteers</article-title>. <source>Biomed Chromatogr</source>
<year>2008</year>;<volume>22</volume>:<fpage>590</fpage>&#x02013;<lpage>5</lpage>.<pub-id pub-id-type="pmid">18254152</pub-id></mixed-citation></ref><ref id="eci12771-bib-0022"><label>22</label><mixed-citation publication-type="journal" id="eci12771-cit-0022">
<string-name>
<surname>Moreno</surname>
<given-names>RP</given-names>
</string-name>, <string-name>
<surname>Metnitz</surname>
<given-names>PG</given-names>
</string-name>, <string-name>
<surname>Almeida</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Jordan</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Bauer</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Campos</surname>
<given-names>RA</given-names>
</string-name>
<italic>et al</italic>
<article-title>SAPS 3&#x02013;from evaluation of the patient to evaluation of the intensive care unit. Part 2: development of a prognostic model for hospital mortality at ICU admission</article-title>. <source>Intensive Care Med</source>
<year>2005</year>;<volume>31</volume>:<fpage>1345</fpage>&#x02013;<lpage>55</lpage>.<pub-id pub-id-type="pmid">16132892</pub-id></mixed-citation></ref><ref id="eci12771-bib-0023"><label>23</label><mixed-citation publication-type="journal" id="eci12771-cit-0023">
<string-name>
<surname>Vincent</surname>
<given-names>JL</given-names>
</string-name>, <string-name>
<surname>de Mendonca</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Cantraine</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Moreno</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Takala</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Suter</surname>
<given-names>PM</given-names>
</string-name>
<italic>et al</italic>
<article-title>Use of the SOFA score to assess the incidence of organ dysfunction/failure in intensive care units: results of a multicenter, prospective study. Working group on &#x0201c;sepsis&#x02010;related problems&#x0201d; of the European Society of Intensive Care Medicine</article-title>. <source>Crit Care Med</source>
<year>1998</year>;<volume>26</volume>:<fpage>1793</fpage>&#x02013;<lpage>800</lpage>.<pub-id pub-id-type="pmid">9824069</pub-id></mixed-citation></ref><ref id="eci12771-bib-0024"><label>24</label><mixed-citation publication-type="journal" id="eci12771-cit-0024">
<string-name>
<surname>Fuchs</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Spiel</surname>
<given-names>AO</given-names>
</string-name>, <string-name>
<surname>Frossard</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Derhaschnig</surname>
<given-names>U</given-names>
</string-name>, <string-name>
<surname>Riedmuller</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Jilma</surname>
<given-names>B</given-names>
</string-name>. <article-title>Platelet hyperfunction is decreased by additional aspirin loading in patients presenting with myocardial infarction on daily aspirin therapy</article-title>. <source>Crit Care Med</source>
<year>2010</year>;<volume>38</volume>:<fpage>1423</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="pmid">20400900</pub-id></mixed-citation></ref><ref id="eci12771-bib-0025"><label>25</label><mixed-citation publication-type="journal" id="eci12771-cit-0025">
<string-name>
<surname>Reilly</surname>
<given-names>IA</given-names>
</string-name>, <string-name>
<surname>FitzGerald</surname>
<given-names>GA</given-names>
</string-name>. <article-title>Inhibition of thromboxane formation in vivo and ex vivo: implications for therapy with platelet inhibitory drugs</article-title>. <source>Blood</source>
<year>1987</year>;<volume>69</volume>:<fpage>180</fpage>&#x02013;<lpage>6</lpage>.<pub-id pub-id-type="pmid">3790723</pub-id></mixed-citation></ref><ref id="eci12771-bib-0026"><label>26</label><mixed-citation publication-type="journal" id="eci12771-cit-0026">
<string-name>
<surname>Patrignani</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Tacconelli</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Piazuelo</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Di Francesco</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Dovizio</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Sostres</surname>
<given-names>C</given-names>
</string-name>
<italic>et al</italic>
<article-title>Reappraisal of the clinical pharmacology of low&#x02010;dose aspirin by comparing novel direct and traditional indirect biomarkers of drug action</article-title>. <source>J Thromb Haemost</source>
<year>2014</year>;<volume>12</volume>:<fpage>1320</fpage>&#x02013;<lpage>30</lpage>.<pub-id pub-id-type="pmid">24942808</pub-id></mixed-citation></ref><ref id="eci12771-bib-0027"><label>27</label><mixed-citation publication-type="journal" id="eci12771-cit-0027">
<string-name>
<surname>Eikelboom</surname>
<given-names>JW</given-names>
</string-name>, <string-name>
<surname>Hirsh</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Weitz</surname>
<given-names>JI</given-names>
</string-name>, <string-name>
<surname>Johnston</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Yi</surname>
<given-names>Q</given-names>
</string-name>, <string-name>
<surname>Yusuf</surname>
<given-names>S</given-names>
</string-name>. <article-title>Aspirin&#x02010;resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events</article-title>. <source>Circulation</source>
<year>2002</year>;<volume>105</volume>:<fpage>1650</fpage>&#x02013;<lpage>5</lpage>.<pub-id pub-id-type="pmid">11940542</pub-id></mixed-citation></ref><ref id="eci12771-bib-0028"><label>28</label><mixed-citation publication-type="journal" id="eci12771-cit-0028">
<string-name>
<surname>Kakouros</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Nazarian</surname>
<given-names>SM</given-names>
</string-name>, <string-name>
<surname>Stadler</surname>
<given-names>PB</given-names>
</string-name>, <string-name>
<surname>Kickler</surname>
<given-names>TS</given-names>
</string-name>, <string-name>
<surname>Rade</surname>
<given-names>JJ</given-names>
</string-name>. <article-title>Risk factors for nonplatelet thromboxane generation after coronary artery bypass graft surgery</article-title>. <source>J Am Heart Assoc</source>
<year>2016</year>;<volume>5</volume>:<fpage>e002615</fpage>.<pub-id pub-id-type="pmid">27068626</pub-id></mixed-citation></ref><ref id="eci12771-bib-0029"><label>29</label><mixed-citation publication-type="journal" id="eci12771-cit-0029">
<string-name>
<surname>Karim</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Habib</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Levy&#x02010;Toledano</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Maclouf</surname>
<given-names>J</given-names>
</string-name>. <article-title>Cyclooxygenase&#x02010;1 and &#x02010;2 of endothelial cells utilize exogenous or endogenous arachidonic acid for transcellular production of thromboxane</article-title>. <source>J Biol Chem</source>
<year>1996</year>;<volume>271</volume>:<fpage>12042</fpage>&#x02013;<lpage>8</lpage>.<pub-id pub-id-type="pmid">8662657</pub-id></mixed-citation></ref><ref id="eci12771-bib-0030"><label>30</label><mixed-citation publication-type="journal" id="eci12771-cit-0030">
<string-name>
<surname>Guthikonda</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Lev</surname>
<given-names>EI</given-names>
</string-name>, <string-name>
<surname>Patel</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>DeLao</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Bergeron</surname>
<given-names>AL</given-names>
</string-name>, <string-name>
<surname>Dong</surname>
<given-names>JF</given-names>
</string-name>
<italic>et al</italic>
<article-title>Reticulated platelets and uninhibited COX&#x02010;1 and COX&#x02010;2 decrease the antiplatelet effects of aspirin</article-title>. <source>J Thromb Haemost</source>
<year>2007</year>;<volume>5</volume>:<fpage>490</fpage>&#x02013;<lpage>6</lpage>.<pub-id pub-id-type="pmid">17319904</pub-id></mixed-citation></ref><ref id="eci12771-bib-0031"><label>31</label><mixed-citation publication-type="journal" id="eci12771-cit-0031">
<string-name>
<surname>Cipollone</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Patrignani</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Greco</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Panara</surname>
<given-names>MR</given-names>
</string-name>, <string-name>
<surname>Padovano</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Cuccurullo</surname>
<given-names>F</given-names>
</string-name>
<italic>et al</italic>
<article-title>Differential suppression of thromboxane biosynthesis by indobufen and aspirin in patients with unstable angina</article-title>. <source>Circulation</source>
<year>1997</year>;<volume>96</volume>:<fpage>1109</fpage>&#x02013;<lpage>16</lpage>.<pub-id pub-id-type="pmid">9286937</pub-id></mixed-citation></ref><ref id="eci12771-bib-0032"><label>32</label><mixed-citation publication-type="journal" id="eci12771-cit-0032">
<string-name>
<surname>Bernard</surname>
<given-names>GR</given-names>
</string-name>, <string-name>
<surname>Wheeler</surname>
<given-names>AP</given-names>
</string-name>, <string-name>
<surname>Russell</surname>
<given-names>JA</given-names>
</string-name>, <string-name>
<surname>Schein</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Summer</surname>
<given-names>WR</given-names>
</string-name>, <string-name>
<surname>Steinberg</surname>
<given-names>KP</given-names>
</string-name>
<italic>et al</italic>
<article-title>The effects of ibuprofen on the physiology and survival of patients with sepsis. The Ibuprofen in Sepsis Study Group</article-title>. <source>N Engl J Med</source>
<year>1997</year>;<volume>336</volume>:<fpage>912</fpage>&#x02013;<lpage>8</lpage>.<pub-id pub-id-type="pmid">9070471</pub-id></mixed-citation></ref><ref id="eci12771-bib-0033"><label>33</label><mixed-citation publication-type="journal" id="eci12771-cit-0033">
<string-name>
<surname>Ulehlova</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Slavik</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Krcova</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Hutyra</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Galuszka</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Indrak</surname>
<given-names>K</given-names>
</string-name>. <article-title>The assessment of aspirin resistance by using light transmission and multiple electrode aggregometry</article-title>. <source>Int J Lab Hematol</source>
<year>2011</year>;<volume>33</volume>:<fpage>305</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="pmid">21219589</pub-id></mixed-citation></ref><ref id="eci12771-bib-0034"><label>34</label><mixed-citation publication-type="journal" id="eci12771-cit-0034">
<string-name>
<surname>Aksu</surname>
<given-names>HU</given-names>
</string-name>, <string-name>
<surname>Oner</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Celik</surname>
<given-names>O</given-names>
</string-name>, <string-name>
<surname>Isiksacan</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Aksu</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Uzun</surname>
<given-names>S</given-names>
</string-name>
<italic>et al</italic>
<article-title>Aspirin resistance in patients undergoing hemodialysis and effect of hemodialysis on aspirin resistance</article-title>. <source>Clin Appl Thromb Hemost</source>
<year>2015</year>;<volume>21</volume>:<fpage>82</fpage>&#x02013;<lpage>6</lpage>.<pub-id pub-id-type="pmid">23698727</pub-id></mixed-citation></ref><ref id="eci12771-bib-0035"><label>35</label><mixed-citation publication-type="journal" id="eci12771-cit-0035">
<string-name>
<surname>Kempfert</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Anger</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Rastan</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Krabbes</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Lehmann</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Garbade</surname>
<given-names>J</given-names>
</string-name>
<italic>et al</italic>
<article-title>Postoperative development of aspirin resistance following coronary artery bypass</article-title>. <source>Eur J Clin Invest</source>
<year>2009</year>;<volume>39</volume>:<fpage>769</fpage>&#x02013;<lpage>74</lpage>.<pub-id pub-id-type="pmid">19674078</pub-id></mixed-citation></ref><ref id="eci12771-bib-0036"><label>36</label><mixed-citation publication-type="journal" id="eci12771-cit-0036">
<string-name>
<surname>Stissing</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Dridi</surname>
<given-names>NP</given-names>
</string-name>, <string-name>
<surname>Ostrowski</surname>
<given-names>SR</given-names>
</string-name>, <string-name>
<surname>Bochsen</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Johansson</surname>
<given-names>PI</given-names>
</string-name>. <article-title>The influence of low platelet count on whole blood aggregometry assessed by multiplate</article-title>. <source>Clin Appl Thromb Hemost</source>
<year>2011</year>;<volume>17</volume>:<fpage>E211</fpage>&#x02013;<lpage>7</lpage>.<pub-id pub-id-type="pmid">21406416</pub-id></mixed-citation></ref><ref id="eci12771-bib-0037"><label>37</label><mixed-citation publication-type="journal" id="eci12771-cit-0037">
<string-name>
<surname>Hovens</surname>
<given-names>MM</given-names>
</string-name>, <string-name>
<surname>Snoep</surname>
<given-names>JD</given-names>
</string-name>, <string-name>
<surname>Eikenboom</surname>
<given-names>JC</given-names>
</string-name>, <string-name>
<surname>van der Bom</surname>
<given-names>JG</given-names>
</string-name>, <string-name>
<surname>Mertens</surname>
<given-names>BJ</given-names>
</string-name>, <string-name>
<surname>Huisman</surname>
<given-names>MV</given-names>
</string-name>. <article-title>Prevalence of persistent platelet reactivity despite use of aspirin: a systematic review</article-title>. <source>Am Heart J</source>
<year>2007</year>;<volume>153</volume>:<fpage>175</fpage>&#x02013;<lpage>81</lpage>.<pub-id pub-id-type="pmid">17239674</pub-id></mixed-citation></ref><ref id="eci12771-bib-0038"><label>38</label><mixed-citation publication-type="journal" id="eci12771-cit-0038">
<string-name>
<surname>Derhaschnig</surname>
<given-names>U</given-names>
</string-name>, <string-name>
<surname>Schweeger&#x02010;Exeli</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Marsik</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Cardona</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Minuz</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Jilma</surname>
<given-names>B</given-names>
</string-name>. <article-title>Effects of aspirin and NO&#x02010;aspirin (NCX 4016) on platelet function and coagulation in human endotoxemia</article-title>. <source>Platelets</source>
<year>2010</year>;<volume>21</volume>:<fpage>320</fpage>&#x02013;<lpage>8</lpage>.<pub-id pub-id-type="pmid">20608787</pub-id></mixed-citation></ref><ref id="eci12771-bib-0039"><label>39</label><mixed-citation publication-type="journal" id="eci12771-cit-0039">
<string-name>
<surname>Sai</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Kusaka</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Imanishi</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Matsumoto</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Takahashi</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Sugimoto</surname>
<given-names>N</given-names>
</string-name>
<italic>et al</italic>
<article-title>A randomized, quadruple crossover single&#x02010;blind study on immediate action of chewed and unchewed low&#x02010;dose acetylsalicylic acid tablets in healthy volunteers</article-title>. <source>J Pharm Sci</source>
<year>2011</year>;<volume>100</volume>:<fpage>3884</fpage>&#x02013;<lpage>91</lpage>.<pub-id pub-id-type="pmid">21544823</pub-id></mixed-citation></ref></ref-list></back></article>